Best Practices
in Vaccines

Overview

We are delighted to announce the IVLC which is going to be held in MUMBAI during 25Th & 26Th AUGUST, 2022. The IVLC strives to provide a meaningful theme of “BEST PRACTICES IN VACCINES” & will assemble leading specialists from around the world including researchers, scientists, academicians, vaccinologists, immunologists, healthcare professionals, clinicians, government representatives & industry delegates who will share their knowledge on the field’s most recent ground-breaking advancements & discoveries, including the front-runner COVID vaccines.

IVLC 2022 will demonstrate how vaccination helps to improve the health of everyone, everywhere throughout life, by connecting us to the people, ambitions, & moments that matter most to us. The IVLC is made up of a variety of keynote sessions, plenary talks, oral & poster presentations aimed, as well as a terrific opportunity to network with peers from industry. The summit provides a one-of-a-kind opportunity for all industry leaders, specialists, investors, corporate investors, & business development executives to meet with elite business representatives & increase the chances of marketing in this networking world.

We hope to meet you at IVLC 2022, which will not only open doors to your profession, but also to future opportunities, new cultures, & global perspectives.

Key Highlights

150

Attendees

40

Speakers

4

Media Partners

4

Association Partners

Why Attend

Get strategic insights from Vaccines thought leaders and network with industry professionals who are reimagining the future of Vaccine Industry.
Find out how your strategy, planning and solutions benchmark against your competition.
Get to see and understand cutting-edge technology solutions. Connect and engage with thought leaders and business professionals from across Globe.

Who will Attend

Vaccines Companies

Manufacturing

Research & Development

Clinical Trials

CEOs, CSOs, Presidents, VPs, GM, DGM & AGM

Scientists/ Engineers/ Technicians Regulatory Affairs/ Business

Development/ Marketing

Others

Keynote Address

Mr Sanjiv Navangul

Managing Director & CEO Bharat Serums and Vaccines Limited

Sanjiv Navangul has led a host of global pharmaceutical companies to operational success. His mentorship and contribution towards a values-based culture is widely acknowledged by business leaders. Mr. Navangul has served on the board of Johnson & Johnson Pvt Ltd. India, and Fulford India. Mr. Navangul has held several leadership roles through his 30 year career such as Managing Director for Janssen (Pharmaceutical Division of Johnson & Johnson) in India and South Asia; Managing Director for MSD Pharmaceuticals, Philippines; Commercial Director for MSD India and South Asia.

A recipient of several industry awards on Public Health, Marketing and Diversity, Mr. Navangul has also served as the Vice President of OPPI (Organisation of Pharmaceutical Producers of India) from 2014 to 2019, Chairman of AMCHAM Pharma committee (American Chamber of Commerce) from 2016 to 2019 and Chairman, Medical and Regulatory Committee from 2016 to 2019. He has been on the Academic Board of NMMIS Pharma management, IES Management school and IIHMR, Jaipur.

Dr. Bakulesh M. Khamar

Executive Director – Research & Development, Cadila Pharmaceuticals Limited

Professional Experience

Bakulesh Khamar is Executive Director-R&D at Cadila Pharmaceuticals Ltd, India since 1996 and he is responsible for bringing innovations at Cadila. After obtaining his M.S. in 1980, he has been an active teacher and researcher and worked at M&J institute of ophthalmology- Ahmedabad, N.H.L. Municipal Medical College-Ahmedabad, Shankara Netralaya- Chennai and School of Optometry, Berkeley, University of California, USA. His earlier part of the carrier was restricted to eye research only. In that duration, he developed K-M Medium for corneal preservation, device for Visual activity prediction in presence of opaque media, device for visual filed screening. He also received numerous awards including Col. Rangachari Award by All India Ophthalmic society for best paper. After joining CADILA, he has started working on other areas of human health for converting knowledge in to products for healthcare interventions, key highlights are:

  • Sepsivac – repurposing of an approved immunomodulator for
    • Prevention of COVID-19
    • Treatment of critically ill patients suffering from COVID-19
    • Improving prophylactic efficacy of vaccines against SARS-CoV-2 variants
  • Subunit Rabies G vaccine - world’s first subunit recombinant protein containing rabies vaccine for post exposure prophylaxis. It reduces the no. of doses to 3 from 5 needed for conventional inactivated virus containing vaccine.
  • Sepsivac - world’s first immunomodulator approved for the management of gram-negative sepsis along with standard of care for reducing the morbidity and mortality
  • Seasonal Influenza vaccine - first VLP vaccine for influenza.
  • H1N1 Influenza vaccine - VLP vaccine for H1N1.
  • Polycap - novel and world’s first polypill for prevention of cardiovascular diseases
  • Mycidac-C - world’s first targeted active immunotherapy for non-small cell lung cancer.
  • Intravenous (IV) Rabeprazole - first in world to raises intragastric ph. above 6.0 within 10 minutes of administration
  • Risorine - novel formulation of Rifampicin with piperine, the bio enhancer

Subhra R. Chakrabarti

PhD Director (Operations)-BIRAC

Dr. Subhra Ranjan Chakrabarti is the Director (Operations) of at Biotechnology Industry Research Assistance Council (BIRAC), Department of Biotechnology, Government of India. Prior to this, he was the Associate Vice President and Manufacturing Technology Leader for South for Global Program with Sanofi Healthcare India Private Limited (Previously Shantha Biotechnics), Hyderabad. He has eight years of research experience in the academic environment and concurrent twenty years in a leading Biotechnology Company in the area of vaccines, Monoclonal Antibodies, Recombinant therapeutics, and cancer research. During this period, he has contributed significantly in all the areas of product value chain. Dr. Chakrabarti also lead several successful vaccine manufacturing technology transfer and validations. He obtained his PhD in Biophysics and Molecular Biology from University of Calcutta. He completed his post-doctoral research at the Cardinal Bernardin Cancer Center, LUMC, Illinois, USA. He has several publications to his credit.

Special Address

Dr. Renu Swarup

Former Secretary to Government of India, Department of Biotechnology, Ministry of Science & Technology, New Delhi

Former Secretary, Department of Biotechnology (DBT), Government of India. Having served in the Department of Biotechnology for over 30 years, she was also the Chairperson of Biotechnology Industry Research Assistance Council (BIRAC), She also held the Additional Charge of Secretary Department of Science &Technology for a short period .
A PhD in Genetics and Plant Breeding, She did her Post Doctoral Research at The John Innes Centre, Norwich UK, Dr. Renu Swarup has been instrumental in the planning and implementation of some major National programmes. As a Science Manager issues related to policy planning and implementation were a part of her assignment. She was actively engaged in the formulation of National Biotechnology Vision and Strategy in 2001, 2007 and 2015and 2021.She was also a member of the Task Force on Women in Science constituted by the Scientific Advisory Committee to the Prime Minister.
As the Secretary of Government of India, Department of Biotechnology, she led a Network of 16 Autonomous Research Institutes, 2 Public Sector Undertaking and a R&D Network of more than 5000 projects across more than 100 research institutes, Universities and Laboratories. In the recent COVID Pandemic situation she led the COVID Vaccine ,Diagnostic and Genome sequencing Mission. The Public Sector BIRAC, for which she was the founding Managing Director and then Chairperson, has supported more than 5000 Startups and over 60 Incubators
A Fellow of the National Academy of Sciences (NASI) India, A Life Member of Trust for Advancement of Agricultural Sciences (TAAS) and a Member of the Organization for Women in Science for the Developing World (OWSD), she was awarded the “BioSpectrum Person of the Year Award” in 2012. “National Entrepreneurship Awards 2017”, TiE Award 2018, “Dr. P. Sheel Memorial Lecture Award” 2018 by NASI and the TWAS Regional Office Prize on Science Diplomacy in 2018. She has been awarded the Agriculture Research Leadership Award 2019.

Advisory Board Member

Dr Manoj Kumar Chhikara

Vaccine R&D and One Health Enthusiast

Dr. Manoj Kumar is a PhD in Veterinary Bacteriology and has worked for over 2 decades in Biotech and Microbiology research with a successful Industry career while working at different leadership positions in Biological E Ltd, Hyderabad, MSD Wellcome Trust Hilleman Labs, New Delhi and Serum Institute of India, Pune.

He is a Vaccine R&D Leader, a Microbiologist and a ONE HEALTH enthusiast with extensive experience in early- to late-stage R&D programs and technology transfers. He has worked on projects spanning academic labs to industry research labs, to development labs and on to manufacturing and quality control settings. He is a proven leader in GLP, GCLP and GMP settings of developing countries for antigen design, process, analytical, formulation, preclinical and clinical development of diverse vaccines and bio-therapeutic products. He is well-versed in scientific, CMC and regulatory requirements in India.

His has contributed to R&D of 27 conjugate vaccine antigens, 6 synthetic vaccine antigens, 8 protein subunit vaccine antigens, 6 viral vaccines, 4 recombinant therapeutic products and 15 diagnostic monoclonal antibodies.

Some of his key achievements are:
20 national & international awards and honors
18 Successful Technology Transfers (R&D to R&D; R&D to QC; R&D to Manufacturing)
Investigator for 6 Pre-clinical toxicity studies
Led 5 Clinical serology projects
5 Successful Grant proposals
18 Patent applications (several already granted in different countries)

Publications:
Editorial (1),
Peer-Reviewed Research Papers (15),
WHO TRS (1),
WHO reports as contributing scientist (3)
Book Chapters (2),
Popular articles (5),
Published Abstracts (>30),
Press releases (31)

Scientific Leadership:
Participated as member of 13 Advisory Committees,
Presented 29 Invited Presentations/Lectures,
Chaired/Co-Chaired 6 Meetings,
Memberships of 10 scientific societies,
Reviewer for 14 Scientific Journals,
Member of Editorial Board of 4 journals,
Has guided 1 PhD and >20 Master’s Degree students as industry co-guide

Dr Ranjan Chakrabarthi

Former Vice President, Global Biologics United States Pharmacopeia

Dr. Ranjan Chakrabarti has over 34 years of experience in Pharmaceutical and Biopharma industries. Dr. Ranjan Chakrabarti is now working as an Independent Consultant and advising Telangana State, NIPER and several Conference organizers. He was the Vice President – Global Biologics at United States Pharmacopeia. During his tenure in USP, he was overseeing scientific outreach activities in South, SE Asia and China. He was also overseeing the Biologics Laboratories in India, US & China. Before joining USP, Dr. Ranjan was leading the Biology Group at Dr. Reddy’s Drug discovery and also served at key management position in GVK Biosciences. He has worked with several National and International companies for discovery and development of both chemical and biological molecules. Before joining to Industry, he worked 7 years in Academics at USA and successfully coordinated research projects in Cancer Cell Biology and Diabetes. He has guided several Ph. D. students. Dr. Ranjan is the Co-Inventor of 32 US Patents; published 62 papers in peer reviewed International Journals and presented 96 lectures in International and National Conferences.

Dr. Upendra K. Jani

Consultant Microbiologist, Hester Biosciences Limited

Dr Upendra Jani is working as a Consultant Microbiologist at Hester Biosciences Limited. He has a unique and comprehensive experience of more than 40 years in Human Rabies Vaccine, Poultry Vaccines and Antibiotics Manufacturing arenas with reputed organizations like Cyanamid (I) Ltd., Chemosyn Research Centre, Gujarat Themis Biosyn Ltd., Hoechst (I) Ltd., and Hester Biosciences Ltd. He trained in Germany for production of internationally acclaimed new generation tissue culture based Human Rabies Vaccine and in U.S.A. for the manufacturing of Poultry Vaccines. Several of his scientific articles have been published in journals and presented at national and international conferences and symposia. Dr Jani has also authored a Book: “Lactobacillus acidophilus as a poultry probiotics, Guide to Poultry Probiotics”, published by LAP LAMBERT Academic Publishing, ISBN-13978-3-8473-1545-2, 2011-12-15 and contributed to Book Chapter: “Good Manufacturing Practices (GMP): Planning for Quality and Control in Microbiology” in Frontier Discoveries and Innovations in Interdisciplinary Microbiology, published by Springer, India (2015), ISBN 978-81-322-2609-3. He is an Honorary and Life Member for various national and international organizations, and has engaged as Industry Expert and Faculty Member for Board of Studies with various Universities in Gujarat. Some of his specialties include, Poultry Probiotics, Vaccines-Human and Poultry, Antibiotic Fermentations, Quality Assurance and Good Manufacturing Practices.

Speakers

Dr Raj Shankar Ghosh

Senior Advisor Vaccine Delivery Bill & Melinda Gates Foundation, India

Dr. Raj Shankar Ghosh is a Physician with training in public health. In a career spanning 30 years, Dr Ghosh has focused primarily on infectious diseases and immunization. He has served the National Polio Surveillance Project India of Government of India and World Health Organization as Regional Coordinator of its Southeast Region. As Technical Director at PATH India and Regional Director of JE and VL Projects of PATH, Dr. Ghosh has led multiple projects across countries in Southeast and Western Pacific regions of Asia. He is currently Senior Advisor, Vaccine Delivery at Bill & Melinda Gates Foundation. Dr Ghosh is an honorary Fellow of Indian Public Health Association.

Dr Pradeep Nagalkar

Head Quality Control, Haffkine Bio-Pharma. Corpn. Ltd

Dr. Pradeep Nagalkar is working as a Head, Quality Control at Haffkine Bio-Pharmaceutical Corp. Ltd. since last 21 years. He is responsible for all Quality Control (Chemical and Biological) related to various Vaccines and Antiseras, Pharmaceutical products like tablets, oral liquids.

Dr. Pradeep Nagalkar has over 34 years’ experience in the biotechnology industry, 21 years of his experience is in vaccine industry.

He has completed his post-graduation from Seth G. S. Medical College & K.E.M. Hospital, Parel, Mumbai. He is Ph.D. in Microbiology from University department of Chemical Technology (UDCT), Mumbai. He has Extensive knowledge of Protein purification and Biological testing. He has worked previously with National Plasma Fractionation Centre, Parel, Mumbai and Biological E., Hyderabad.

Dr. Pradeep Nagalkar is also deputed for various workshops and attended many conferences, symposiums and delivered many lecturers in national and international conferences, written scientific articles.

Dr. Ashish Sahai

Additional Director, Production (viral vaccines) at Serum Institute of India Pvt.

Presently an Additional Director, Production (viral vaccines) at Serum Institute of India Pvt. Ltd., Pune, India. Trained in regulatory affairs at UMASS in Boston, USA and Chumakov Institute, Moscow, Russia. He is Ex.IITian and has a Doctorate in virology with more than 33 years of rich experience in various departments such as production, quality assurance, quality control in the Biotechnological industry and Research Institute. He has expertise in upstream processing of viral vaccines. He is specialized in purification of viral vaccines and has developed WHO approved Oral polio vaccine and Rabies vaccine at SIIPL.

Dr. Ivana Haluskova

Vaccines Industry Expert, France

French/Slovak Medical professional specialised in infectious and Tropical (Neglected) diseases, Internal medicine, certified in Immunology,Pediatry and Public health and diplomacy in Switzerland (IHEID), Vaccines and years of Clinical/Medical practise.

Lived multi-country medical “field “experience in Southeast Asia (India in particular), West/Central/East Europe and Middle East.

Speaking French, English, Italian, Russian, Czech/Slovak.

Over 10 years of experience as consultant/scientific expert and medical lead in pharmaceutical research and development for European and USA companies(Servier, Wyeth/Pfizer,Flamel technologies as global medical lead and medical director of clinical and preclinical development) within various therapeutic areas covering complex international projects.

Supporting research and cooperation around Microbiota/Immunity (certified CIMI Microbiota medical application Paris) Focus on better understanding of host immune system - pathogen-microbiota interactions for adapted intervention in transversal way including joint interest withing infectious diseases /cancer and common targets (e.g viruses/immune-oncology).

Supporting direction of Prevention and Early diagnostic (innovative biomarkers) in clinical practice and Medical care.

Member of international advisory groups (CHD India) and think tank groups in order to foster global cooperation in areas of Public health with Europe.

Speaker at various international conferences and Member of administrative boards of French academia (WAAR- antibiotic resistance, French immunology society).

Years of expertise to work globally but more focused on Asia(India in particular) and broader Eurasian cooperation as a Medical advisor bringing new innovative concepts alive and getting them endorsed.

Dr. Rajendar Burki

PhD, Associate Vice President, (R&D) Biological E. Limited,

Dr. Rajendar Burki is currently working as AVP, at R&D, Biological E Limited. Heading Analytical, Glyco-Conjugation and Formulation development activities.

He received Ph.D. degree in Bioanalytical/Biological Chemistry from Tohoku University (Japan), followed by postdoctoral training at University of Alabama at Birmingham (USA).

Authored 10 patents, 20+ international publications and delivered talks in National and international conferences.

His expertise includes Analytical development and characterization, conjugation of biomolecules with markers and polysaccharides including process development of biopharmaceuticals.

Dr Sudeep Kumar

Sr VP Biological E Limited

Dr Sudeep Kumar did his Post Doc in Biotech from Valencia. He has more than 20 years of experience in Biopharma from Large scale fermentation based product to recombinant therapeutic proteins, Vaccines and Diagnostic kit. He has vast experience from R&D to commercialization of recombinant proteins, Vaccines and Diagnostic kit with good understanding of regulatory requirement.

He has worked from R&D to tech transfer and manufacturing of different molecule. During his tenure he was involved in dealing with different regulatory agencies for approval and faced WHO, USFDA and other regulatory audits. He also actively involved with clinical research team for Preclinical and clinical trials of recombinant proteins and vaccine. He developed and commercialized many recombinant proteins, vaccines and rapid diagnostic kit.

He established the VLP technology platform for different vaccine in India in collaboration with Novavax and taken the approval for this new concept technology. He is actively involved in the development of novel therapeutic protein for cancer therapy.

He has worked with Ranbaxy, Cadila pharma, Unichem and now at present he is working as Senior Vice president at Biological E, Hyderabad.

Annu Uppal

PhD, Associate Scientific Affairs Director, USP-India

Annu Uppal is currently working as Associate Director- Scientific Affairs at United States Pharmacopeia (USP)-India. In her role, she is leading the USP’s initiative of Knowledge hub for Multi Attribute Methods (MAM), scientific engagement activities and external collaborations. She is also an approved faculty for USP Education programs and regularly conducts various webinar and education programs.

Annu is core mass spectrometric expert with >15 years of experience in analytical method development, validation, product characterization, impurity profiling, glycan analysis. Before joining USP, she was leading the mass spectrometric applications globally for monoclonal antibodies & other biotherapeutics at SCIEX. Annu was instrumental in setting basic and advanced mass spectrometry-based workflows like glycan profiling, disulfide linkages elucidation, multi attribute methodology, native mode analysis and host cell protein analysis for therapeutic antibodies. She also has expertise in the analysis of peptides, Metabolites, Lipids, Biomarker Discovery/Verification workflows. Annu has more than 30 research papers and book chapters in peer reviewed journals. She has presented in several National and International Conferences as Invited speaker.

Rajendra Lingala

VP & Head - R & D, Indian Immunologicals Limited

Over 30 years of research experience in Vaccine development programs, Technical due diligence, Pilot facility design & execution, Process development, Process validation, Formulation development for thermostable vaccines, Clinical batches manufacturing, cGMP fill finish, Clinical trials, Regulatory filing and approvals. Successfully transferred the manufacturing process for various vaccine candidates from R & D scale to commercial scale.

Served in different capacities at Indian Immunologicals Limited overseeing the process development for various Bacterial & Viral vaccines (Recombinant & Conventional), Conjugate vaccines, Monoclonal antibodies & Bio-therapeutics.

Fields of expertise include Process Development, Formulation Development – Thermostable vaccines, vaccine delivery devices and combination vaccines for Pediatric use.

Prior to joining Indian Immunologicals Limited served as Sr. General Manager, Bio Process Head at Shantha Biotechniques Limited (A Sanofi Company) and as Senior Director at MSD Wellcome Trust Hilleman Labs overseeing analytical and formulation development.

Dr. Vasan Sambandamurthy

Senior Vice President – Strategy & Global Operations at Bugworks Research Inc

Dr. Vasan Sambandamurthy is Senior Vice President – Strategy & Global Operations at Bugworks Research Inc – a clinical stage biopharmaceutical company that is developing novel class of broad-spectrum antibacterial agents and immunotherapies to treat patients with critical care needs in infection and cancer.

Vasan brings over 20 years of professional experience in vaccine discovery and drug development at major global corporations like Novartis, AstraZeneca, and Biocon. At these organisations he has held senior leadership positions, provided strategic directions, and orchestrated major business operations to develop affordable medicines across multiple therapeutic areas including oncology, diabetes, infectious diseases (specifically against tuberculosis and malaria) and inflammation. Most recently, he was the Chief Executive Officer at the DBT/Wellcome Trust India Alliance, a major global funding agency (annual budget of £24 million) promoting basic, biomedical and clinical research across India. He has over 50 publications in peer-reviewed international journals including Nature Medicine, Nature Immunology, Nature Communications and co-inventor on 4 patents.

Dr. Kutub Mahmood

Scientific Director, Path, USA

Senior biotech executive professional with expertise in viral vaccines with 30yrs experience in vaccine development with focus on CMC, pre-clinical animal studies and clinical studies including clinical samples testing. Currently at PATH, leading and managing projects for vaccines and biologics including product development strategies for compliance with GMP and/or GLP practices as applicable for national and international regulatory framework compliance (WHO, FDA, EMA,DCGI, NMPA). Experience in national regulatory approvals and for achieving WHO pre-qualification for vaccine products. Currently project lead for polio vaccines development and scaleup for OPV and IPV related work. Current and past projects at PATH includes work related to measles-rubella, influenza, RSV, Yellow fever, live rotavirus, and SARS-CoV2 with technologies including whole virion, inactivated, vectored, live attenuated, VLPs and subunit vaccines. Holds national and international patents on VLP technology for influenza and RSV vaccines, and include publications in peer-reviewed journals. Presently serves on several scientific panels for national and international vaccine meetings, also serves as scientific reviewer for manuscripts submitted for publications in journals including Vaccine, Journal of Infectious Diseases, Emerging Infectious Diseases, and Human Vaccines & Therapeutics.

Pradnya Deshmukh

President, Head Global Quality and Compliance, Wockhardt Ltd.

A seasoned professional with three decades of experience with driven by purpose of serving patient and adding value to healthy life style.

Expert on strategic planning , balancing business and compliance for growth of industry.

Masters in analytical and medicinal chemistry . certified Lead auditor on quality management system and environment management from BVQI UK.

Enjoy working in diversified culture across the global geographic locations .

Expertise in handing regulatory audits, agencies communication, Acquisitions and merger processes. Quality control and assurance process.

Responsible for development of product to distribution – life cycle of product quality for uninterrupted compliant supply chain management across the organization.

She has worked for Ipca laboratories, Sun pharma , ACG group at various positions to gather expertise on quality, compliance, and strategic approach.

Sivasankar Baalasubramanian (Shiv) PhD

CEO Stealth Startup

Shiv is a scientist turned entrepreneur with over 20 years of global experience in innovative research in immunology, combined with strong business and leadership accomplishments through entrepreneurship.

He is currently the CEO of stealth startup, an immunodiagnostics startup presently focused on the science of COVID-19 immunity elicited via infection or vaccination. The Startup has been involved with COVID-19 vaccine manufacturers, and academic institutions, in establishing and evaluating the cellular immunity to COVID-19. Shiv has spearheaded the establishment of various platforms at the startup that are instrumental in understanding a vaccine’s efficacy in eliciting and sustaining both T and B cell response, and further exploring how these responses are modulated under various booster dose combinations. In addition, the startup developed a simple and rapid, blood-based test that will allow one to test for T cell immunity against COVID-19 without requiring high-end research infrastructure. The test has now been used by vaccine manufacturers to screen study subjects for inclusion in, or exclusion from, a study or clinical trial. These robust and multi-faceted platforms that the startup has developed for the in-depth study of COVID-19 vaccines is easily adaptable to any disease and vaccine, depending on the need of the hour, in an accelerated timeframe.

Shiv’s previous entrepreneurial experience saw him embark on an ambitious mission to build and establish a high-end products and services entity for the UK/US-based Indoor Biotechnologies in the Asia Pacific market for immunology and allergy needs. He served as its executive director for over 6 years and during his highly successful tenure, he developed and marketed a vast portfolio of cuttingedge, innovative solutions in the areas of immunology, allergy, inflammation, immuno-oncology, and anti-viral testing. The company catered to academia and industries involved in the development of biologics, diagnostics and FMCG products.

During his career in academia, Shiv served as a Principal Investigator at the Singapore Institute for Clinical Sciences, where he built and established a new research program to probe the immunobiology of viral diseases leading to the demonstration of the seminal role of the complement system in survival following influenza infection.

Prior to this, Shiv was a recipient of the prestigious Wellcome Trust traveling and research fellowship, leading him to the School of Medicine, Cardiff University, UK, where he identified a unique and previously unknown role for CD59 in augmenting T cell immunity in infection and cancer.

Shiv has an award-winning Ph.D. in Immunology from the esteemed All India Institute of Medical Sciences (AIIMS), New Delhi.

Dr. Ravi Ganapathy

PhD, PGDBA (Ops). Director, CMC R&D HLS (Hilleman Laboratories Singapore Pte Ltd), Singapore

Dr. Ravi Ganapathy has over 29 years of professional work experience in the hospital, biotech research & vaccine industry settings. He has hands-on experience in development, manufacturing of recombinant (bacterial/yeast-derived), bacterial and viral vaccines. Having led R&D, Production and Quality Assurance teams he has an extensive understanding of manufacturing and R&D-related quality & regulatory requirements for commercialization of biotech products, especially vaccines, and the related GLP & GMP documentation. He joined Hilleman Laboratories Singapore as the Director–CMC R&D in April 2022.

Immediately prior to joining HLS, Dr. Ganapathy was `Head–Vaccine Development Department’ at the International Vaccine Institute (IVI), Seoul, South Korea for 3 years from May 2019. There his streamlined the technology transfer processes, vaccine process development activities, process/analytical development for new candidate vaccines, etc.; he also contributed to university education programs as `Adjunct Professor’ to Yonsei University and Seoul National University.

Before IVI Dr. Ganapathy he was with Biological E. Ltd., Hyderabad, India for over 5 years, where he helped set-up laboratories, built and led the Manufacturing Sciences team providing full-fledged support to the commercial manufacturing divisions (production & QC) -including Life-Cycle Management involving the introduction of new delivery systems, and technology transfers. Based on the work done under his leadership at BioE, an international patent involving a novel adjuvant preparation process was published.

Prior to BioE, Dr. Ganapathy worked for 2 years at Shantha Biotechnics (a Sanofi company), where he led the scale-up of the manufacturing process of a tetravalent rotavirus vaccine from Phase-I to Phase-III and oversaw the Ph-III material production and delivery. His first vaccine industry experience, however, was with Bharat Biotech International Ltd. where he worked for >14 years, and also completed his PhD through his work on a CDC-NIH-sourced multi-epitope, recombinant malarial vaccine candidate against Plasmodium falciparum. At BBIL Dr. Ganapathy spearheaded teams on projects for manufacturing vaccines for use in several clinical trials (supported by PATH/BMGF, MVI/EVI and DBT-India) and for commercial supplies. He also played a crucial role in product and process development, and in the approval of the first cell culture-derived Pandemic H1N1 Influenza vaccine in India (2009).

Dr. Ganapathy graduated as a double-gold medalist for his post-graduate work in `Medical Entomology’ from VCRC (ICMR) in 1993; and his bachelor’s degree was in `Medical Laboratory Technology’ from JIPMER (1991), both in Pondicherry, India. He has been a lead- or co-author of 11 research papers and has delivered talks at several international conferences and training programs over the last 15 years.

Dr Vinod Pantula

Head Vaccine Development Dr Reddy's Laboratories

Dr Vinod Pantula has over 16 years of experience in vaccine development, specializing in preclinical and early clinical development of vaccines. Presently he is working as the Head of Product Development - Vaccines at Dr Reddy's Laboratories Hyderabad, dedicating his time, effort and ability in establishing a vaccine development facility to develop vaccines for unmet need using modern manufacturing platforms.

Dr. Arun Kumar

Preclinical Vaccines Development Lead Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway

Dr. Arun Kumar is the Preclinical Vaccines Development Lead at the Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway. The main objective of CEPI is to accelerate the development of vaccines against emerging/re-emerging infectious diseases and enable access to these vaccines for people during outbreaks. Dr. Kumar previously held positions at the GlaxoSmithKline Vaccines & Novartis Vaccines and Diagnostics, where he led vaccine development programs based on the mRNA technology. At CEPI, Dr. Kumar is leading programs focusing on mRNA innovations, preclinical vaccine development and co-leading CEPI Centralized Global Laboratory Network. Dr. Kumar holds a Ph.D. in Viral Immunology and Infectious diseases from the University of Helsinki, Finland.

Dr. Subhadra Dravida

CEO Transcell

Dr Subhadra Dravida is the Founder CEO of Transcell group. She will be presenting a Transcell developed revolutionary product (original innovation) named NeuroSAFE - A Next generation, non-animal workstation solution to test predict vaccine safety, adverse events concerns in the conclave. NeuroSAFE developed as an assay system is embedded with AI and ML tools integrating digital platforms with real time microphysiological systems yielding healthy human specific readouts, majorly supporting safe immunization programs in India.

Dr. Arjun Raghuwanshi

General Manager at Gennova Biopharmaceutical

Dr. Arjun Raghuwanshi is currently working as General Manager at Gennova Biopharmaceutical Ltd Pune. Previously he has worked with major Indian biopharmaceutical companies e.g. Intas, Zenotech, and Wockhardt Ltd. to bring 20 years of work experience in the field of downstream process development and manufacturing operations. He has developed novel processes for products like recombinant human insulin, EPO, TNK-tPA, GCSF, PEG GCSF, Peg Asparaginase, Rituximab, Adalimumab and Bevacizumab.

Recently, he has developed a commercial scale process for Linear Plasmid preparation and has been instrumental in developing the purification process for India’s first mRNA vaccine (Gemcovac) for covid-19. In the field of bioprocess development, he has received two global process patents for recombinant GCSF (US 20180223270A1) and TNK-tPA, (US20170210784A1). He has published his research work in the field of malaria and other novel drug candidates in the reputed journals. His research interest includes process development, continuous processing, manufacturing operations, process control, and technological innovations.

Arjun holds a Ph.D. in Biotechnology (SBPPU, Pune), M.Sc. in Biotechnology (DAVV, Indore) and B.Sc. in Biotechnology (Jiwaji University, Gwalior).

Dr. Pragya D Yadav

M.Sc., Ph.D, FNAASc, FIVS, MNAMS, MNASc. Scientist 'F' and Group Leader, Maximum Containment Laboratory

Dr. Pragya Dhruv Yadav is Senior Scientist (Scientist-F) & Head of the Biosafety level-4 laboratory, Asia’s first state of the art facility to handle high-risk pathogens at ICMR-NIV, Pune. During COVID-19 Pandemic, she was involved in timely diagnostic support and development of point-of-care assays, Anti-SARS human IgG-antibody ELISA which was used widely in the country for diagnosis. The first three positive samples were identified from Kerala state having a travel history from Wuhan, China. She has expertise in Molecular biology, translational technology, novel pathogen detection, pre-clinical trials, biosafety and biocontainment. She has contributed significantly to shaping up India’s response to the SARS-CoV-2 pandemic by early isolation of the SARS-CoV-2 and fast tracking the development of the indigenous vaccine and demonstrating the efficacy of COVAXIN™ against the different SARS-CoV-2 variants. Besides this, she had also discovered many novel viruses and quickly provided containment responses and diagnosis for Nipah, Zika, CCHF, KFD and Monkeypox virus outbreaks in the country. She has developed many cost-effective diagnosis assays for CCHF, KFDV, and SARS-CoV-2, which are commercialized. Her work contributed significantly to the beginning of research on highly infectious viral pathogens that helped the prevention and control of outbreaks in India. She has discovered many viral etiological agents such as Crimean Congo hemorrhagic fever, Nipah Zika, Tioman, Oya, Malsoor, Catque, Equine encephalosis and Kundal virus for the first time in India. She has led many outbreak investigations and research on CCHF, Kyasanur Forest Disease, Nipah, Zika, SARS-CoV-2 and Monkeypox. Her expertise in the field of BIorisk Management has been useful in strengthening the diagnostic laboratory network (VRDL) across the country. This has helped in preparedness against public health emergencies posed by Ebola, CCHF, Nipah, Yellow fever, SARS-CoV-2 and Monkeypox. Besides this, as a WHO consultant, she assisted in the evaluation and validation of Biosafety level-3 laboratories in Nepal and Bhutan.
She is recipient of many prestigious awards; amongst them few are Bharat Bhagya Vidhata Samman 2022 and ICMR awards [Major General Saheb Singh Sockey Award, Dr. T Ramchandra Rao Award], Dr. Pran Nath Chhuttani Oration Amritsar Award, Dr Vinod Kumar Bhargava Award from (National Academy of Medical Sciences) and Dr. K.M. Bhansali Oration award, felicitated by Governor of Maharashtra , National Academy of Sciences India (NASI) as COVID warrior. She is fellow of National Academy of Agricultural sciences and member of many National and International committee including ICMR, WHO, CEPI etc.

She has published more than 270 research papers in national and international journals with very high impact factors.

Pramod Survashe

Product Manager, Avantor

A professional holding 18 years of rich experience in Biopharma & process industry. Currently working with Avantor supporting fluid handling technology, handling product management in India while working on innovative fluid handling products & systems. He has been working closely with Biopharma end users in India for the commercial development of fluid handling systems. During his previous instinct Pramod has worked in Steam Engineering & process equipment companies in Technical Sales & Marketing, later switched to product management & innovation role. Pramod graduated with bachelor’s degree in Chemical Engineering & MBA in Marketing.

Jayanta Bhattacharya

PhD. Director, IAVI

Currently I am the Director of the Antibody Translational Research Program established under the THSTI-IAVI Partnership program and Principal Investigator at THSTI, Faridabad. I have over 22 years of research experiences in managing, leading and executing research activities in the area of infectious disease biology. Successfully supervised several Ph.D. graduate students and several under graduates and postgraduates – who are suitably placed in their career pathways. As Head of the Division of Molecular Virology at the ICMR-National AIDS Research Institute, ICMR, Pune, successfully steered various National and International Projects primarily through extramural funding as Principal Investigator between 2006-2012. This includes playing a major role in capacity building, establishing, validating and implementing early HIV diagnosis program at different regional laboratories in India with support from the National AIDS Control Organization (NACO), Ministry of Health & Family Welfare, Govt of India and WHO SEARO. I made significant contributions made towards understanding in genetic and functional diversities of HIV-1 clade C the major circulating subtype globally as part of global virus surveillance as part of HIV vaccine R&D and development of monoclonal antibodies as products against HIV & SARS-CoV-2 prevention and treatment. As Director of the IAVI India laboratory at the Translational Health Science & Technology Institute, Faridabad, India I have been leading since 2013, as lead Principal Investigator and lead scientific coordinator a large number of scientific projects funded by national and international funding agencies and also have supervised a number of Senior and Junior Scientists, Postdocs, and technical staffs. I have also established a very large network of strategic partnerships and collaborations from different institutions and hospital settings at national level as well as from international institutions to help drive our research endeavors in a strategic manner. I have published over 60 papers in peer reviewed journals as lead author and am listed as an inventor in 3 international patents awarded and three more that has been filed and received several prestigious awards including DBT National Bioscience Award in 2013 and fellowship grant from the American Foundation of AIDS Research (amfAR) in 2004.

Dr. Tulip Nuwal

Chief Commercial Officer, OmniBRx Biotechnologies Pvt Ltd

Dr. Tulip Nuwal is the chief commercial officer at OmniBRx Biotechnologies Ltd. He has 12+ years of experience spanning academia and industry. A techno-commercial professional with training in both science and commercial aspects of biotech ventures. In his career, he has donned different hats ranging from lab research to global strategy and operations.

At Omnibrx, he and his team are responsible for bringing the proprietary single-use bioprocessing technology, “CellBRx Bioreactor systems” to the global markets. This technology will enable the vaccine manufacturers to produce vaccines and viral vectors at large scales with ultimate process efficiency and cost effectiveness.

Vinita Hasrajani

Business Development Manager – South Asia, Thermo Fisher Scientific

Vinita epitomizes the new generation of women professional entrepreneurs. Born in a middle-class Business family in Ahmedabad, she was educated in the city. She graduated from St. Xaviers College with a major in Biochemistry & Biotechnology, and went on to pursue her MSc in Biotechnology, graduating in 2010. Initially focused on research, as an undergrad she contributed at Xavier Research Foundation. Thereafter she held positions at some of the most prestigious institutes in the country that includes Centre for DNA Fingerprinting and Diagnostics (CDFD, Hyderabad) where she carried out research on Molecular Diagnosis of Cystic Fibrosis under Dr. Ashwin Dalal, Indian Institute of Advanced Research (IIAR, Gandhinagar) understanding CAX (cation) Transporter diversity for nutrition enhanced crops and phytoremediation under Dr. Rajni Nadgauda and Institute of Genomics & Integrative Biology (IGIB, Delhi) understanding host-pathogen interaction in tuberculosis infection with a focus on lipid metabolism under Dr. Sheetal Gandotra. Fascinated by the potential of translational research – implementing hardcore research to benefit real life – she made a switch to the real world – she joined Sigma Aldrich Chemicals Pvt. Ltd at an Executive position. After a brief stint at Imperial Life Sciences, she joined Thermo Fisher about 6 years ago in a Techno-commercial role. Her outstanding performance in the company – not only surpassing her sales targets by 100% year on year – but also being a good team player, straddling across verticals to bring efficiency and deliver results, and creating a culture of support and working together led to her promotions as the Business Development Manager handling Biopharma & Biotech Business across South Asia in the company. Vinita has a well-rounded personality – she was active in debating and elocution, group activities, and was elected as the Miss World of her school in the Millennium year 2000, barely as she had entered her teens. Her vision is to encourage innovation in the exciting field of vaccination, and eventually to place India globally as a leader in the Biotechnology/ Vaccine space.

Gaurav Arora

General Manager & Head - Procurement Stelis Biopharma

Having 23 + years’ of experience in global procurement and strategic sourcing along with developing and implementing processes for identifying, evaluating, and selecting potential suppliers and negotiating favourable business terms and service level agreements. Well versed with Overall Procurement, Green / Brown Field Project procurement, Strategic Sourcing for Raw Materials and Packaging Materials, Imports, In-Bound Logistics, Vendor Development, ERP System Implementations; Implement Procurement Policies, Contract Manufacturing Sourcing (CMO’s) for Generic Formulations, New Molecule & ANDA Project Sourcing and various Process/Cost Improvisation projects.

Currently heading Global Procurement with Stelis Biopharma, and, previously worked with various reputed companies, like Biocon Limited, Ajinomoto OmniChem, Torrent Pharma, DCM Shriram group, Nectar Lifesciences and Lupin Limited.

On the Education part, I completed an E-MBA in “Operation & Retail Management” from Nagaland Open University and “Masters in Commerce” from Kanpur University and also did a Certification Course in "Supply Chain Management", from SYMBIOSIS Centre of Distance Learning, Pune.

Nimesh Gupta

PhD Chief,Vaccine Immunology Laboratory, National Institute of Immunology

Dr. Nimesh is heading the Vaccine Immunology Laboratory at the National Institute of Immunology, New Delhi. Dr. Nimesh is a virologist and immunologist by training. His team works in the area of virus immunology, and the programs are at the interface of fundamental and translational immunology. Major focus is to understand the biology of T cells, mainly Tfh cells, in the long-lasting protective immunity after vaccination or virus infection in human. Dr Nimesh received several awards from prominent international societies for his significant and novel contribution in the field of T-cell immunology like European Federation of Immunological Societies, the American Association of Immunologist, the Martin Villar haemostasis global award and the ADVAC Fellow of Merieux foundation, France. Dr Nimesh has successfully established a “human immune monitoring and T-cell immunoassay platform” which has been highly instrumental in the COVID-19 research in the country. Dr Nimesh has contributed several high impact publications in the prominent journals like Science Translational Medicine, Nature Microbiology, Nature Communication, Lancet Infectious Disease, Cell Reports etc. He has international and national patents on application of T cells in immunotherapy and vaccinology domain. Dr Nimesh is also serving as the virus immunology expert in several national and international taskforces related to human health.

Dr Syed Khalid Ali

MBBS, MS, PhD, Chief Scientific Officer, Panacea Biotec

Dr Khalid is a medical scientist with expertise in vaccinology and infectious diseases. He is the Chief Scientific Officer at Panacea Biotec, one of the leading vaccine manufacturers from India. Dr Khalid is responsible for overall development of vaccines and biologicals, including a Broadly Protective Beta Corona Virus Vaccine at Panacea. Prior to Panacea, Dr Khalid was Director Clinical R&D at Hilleman Laboratories, he has also worked as a scientist at International Vaccine Institute in Seoul South Korea.

Dr Khalid has studied and practiced medicine in India, followed by graduate education from the University of Texas at San Antonio. He has worked in academic, non-profit and commercial entities. He has authored several publications, patents and received several grant funding from major funding agencies like EDCTP, BMGF, H2020 and CEPI. Dr Khalid has collaborated with and worked in several countries across Asia, Africa, and Europe. Dr Khalid is passionate about promoting health for all by reducing inequity in vaccine access.

Panacea Biotec group (henceforth referred as Panacea Biotec) monitors email communications sent to and from Panacea Biotec in order to protect Panacea Biotec, our employees, customers, suppliers and business partners, from cyber threats and loss of Panacea Biotec Information. Panacea Biotec monitoring is conducted with appropriate confidentiality controls and in accordance with local laws and after appropriate consultation. This email (and any attachments or links within it) may contain information that is confidential, legally privileged or otherwise protected from disclosure. The sender confirms that Panacea Biotec shall not be responsible if this email message is used for any indecent, unsolicited or illegal purposes, which are in violation of any existing laws and the sender shall at all times indemnify Panacea Biotec of any civil and/ or criminal liabilities or consequences. While Panacea Biotec has taken reasonable steps to ensure that this email and any attachments thereto are free from computer viruses and the like, it does not undertake any responsibility for loss or corruption of recipient’s data during transmission. Before opening any email, the recipient should ensure that data is free from any viruses.

Dr. Shraddha Bhange

MD Medical Director, Safety Science

Dr. Shraddha Bhange is a doctor by profession with more than 10 years of experience in pharmacovigilance. She is currently serving as Medical Director and heading pharmacovigilance team of physicians at EVERSANA . She was recently selected as top 10 Medical officers 2022 and her story is featured on cover page of "Women Entrepreneur Magazine".

She has worked in core pharma companies such as NOVARTIS, Wockhardt, AB Science (French Biopharma based in PARIS) and CRO/IT like Cognizant.

She has worked in India and Europe (Paris) and faced various regulatory inspections and worked in various therapeutic areas such as vaccine, oncology, diabetics, neurology, and generics. She has worked on postmarking and phase I to phase III drugs and supported product approvals in US, Europe and India. Shraddha is skilled in various regulatory/health agency regulations, especially USFDA, EMA, MHRA, and DCGI. Her other areas of interest are medical communications, quality assurance, regulatory requirements, audits and inspections.

Dr. Bhange earned her Bachelor of Medicine and Bachelor of Surgery (MBBS) from the Maharashtra University of Health Sciences (MUHS) under the Medical Council of India (MCI), and completed a specialized postgraduate full time program in paraclinical subjects, Msc Biomed tech from Coventry University, United Kingdom.

Wasim Shah

Co-founder Algor supply chain solutions Pvt Ltd ,Head sales and marketing

Having 15 years of rich reefer industry experience in Reefer Container Manufacturing and cold chain transportation. Techno commercial mind well versed with market, competition and trends give edge to identify an opportunities , forecast and design strategy to achieve the set targets and gain desired market share.

Partners

Telecast Partner
Logistic Partner
Industry Partner
Lanyard Partner

OmniBRx Biotechnologies Pvt. Ltd.

OmniBRx is an upstream bioprocessing solutions provider to R&D and cGMP manufacturers in biopharma, CGT and vaccine industries. We manufacture fully automated single-use bioreactors using an indigenously developed and patented DBR technology. Our portfolio consists of CellBRx, MiniBRx and PerfBRx bioreactor systems across multiple scales that are suitable from development to commercial scale. These bioreactors are designed to simplify different types of cell cultures viz. adherent and suspension cultures. These innovative SUBs have the smallest per liter volume footprints and are linearly scalable across all stages of the cell culture process. We provide efficient, cost-effective and high-quality disposable bioprocessing systems with hands-on technical support to help our customers solve complex cell culture challenges.
Associate Partner

Thermo Fisher Scientific Inc

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

Avantor

Avantor®, a Fortune 500 company, is a leading global provider of mission-critical products and services to customers in the biopharma, healthcare, education & government, and advanced technologies & applied materials industries. Our portfolio is used in virtually every stage of the most important research, development, and production activities in the industries we serve. Our global footprint enables us to serve more than 225,000 customer locations and gives us extensive access to research laboratories and scientists in more than 180 countries. We set science in motion to create a better world. More than 13,500 strong, our associates are passionate about our mission to set science in motion to create a better world. We share enthusiasm for innovation, excellence, and achievement. Whether we are collaborating with our customers to advance science or solve multifaceted problems, we help them reach their goals more efficiently and effectively.

Visit our website to learn more about Avantor : https://www.avantorsciences.com/

Knowledge Partner
Exhibit Partner

METTLER TOLEDO

METTLER TOLEDO is a leading global manufacturer of precision instruments. The Company is the world’s largest manufacturer and marketer of weighing instruments for use in laboratory, industrial and food retailing applications. The Company also holds top-three market positions for several related analytical instruments and is a leading provider of automated chemistry systems used in drug and chemical compound discovery and development. In addition, the Company is the world’s largest manufacturer and marketer of metal detection systems used in production and packaging. Additional information about METTLER TOLEDO can be found at “www.mt.com.”

Our Analytical Balances, Titrators, pH meters, Density meters, Refractometers, UV Vis Spectrophotometers, Melting point apparatus and pipettes can be tailored to each customer’s application and provide a fully documented workflow for every quality control lab. Our precision instruments are the foundation of research and quality control labs across the world. Thermal analysis instruments help to improve materials and their thermal behavior. Automated chemistry solutions accelerate development of new chemicals.

METTLER TOLEDO's industrial instruments and software optimize operations from receiving to shipping with solutions for production, end-of-line inspection and logistics. Our solutions provide value to customers with improved product quality increased efficiency and regulatory compliance. Many of our solutions are integrated directly into our customer's ERP systems. Our offering to product inspection market includes industrial scales and terminals; software such as statistical quality control, formulation and batching; metal detectors, checkweighers, x-ray visioning systems; automatic identification, data capture and dimensioning solutions for transportation and logistics; and vehicle weighing solutions.

We have offices across India, which include Mumbai (HO), Ahmedabad, Bangalore, Chennai, Delhi, Kolkata, Mohali, Pune, Secunderabad and Vadodara. Apart from this, we have a Factory at Vasai and Nashik, Application Lab in Hyderabad, Asia Bioburden Lab, International Market Support Group (IMSG), Product Inspection Competency Centre, Mass Calibration Laboratory and Service Competency Centre in Mumbai.

Svan Analytical Instruments Pvt. Ltd

Svan Analytical Instruments Pvt. Ltd collaborates with global industry-leading manufacturers to distribute state-of-the-art instruments for microbiological monitoring and decontamination systems for Pharmaceutical and Life sciences Industry. We offer best-in-market solutions for contamination control, real time monitoring, analysing Total Organic Carbon for purified water, water for injection & cleaning validation applications, Single Use Systems, containment solutions, Aseptic Isolators and transfer chambers
Networking Partner

PEPperPRINT

PEPperPRINT GmbH is a German Biotech company developing infectious disease research solution by offering high-density peptide microarrays. We focus on producing 3D molecular printed peptide libraries- by coupling individual amino acids in situ, thereby offering customized high-density PEPperCHIP® Peptide Microarrays for in-depth analysis of epitopes, antibody validation, antigen discovery. The on-chip synthesis of peptides can be in linear or Cyclic form and our proprietary laser-printing technology can synthesize tens of thousands of peptides directly on the chip.

The viral proteome is translated into overlapping peptides and printed onto glass slides, following which the patient sera is incubated on the chip and antibodies present in the sample bind to epitopes recognized within individual peptides. The resulting response profile may be compared across different samples to monitor B-cell responses over time, or to determine immunodominant epitopes that may be further validated as potential disease-specific biomarkers for IVD development.

Moreover, PEPperPRINT provides the Human Epitome Microarray with more than 23,000 human database epitopes for antibody cross-reactivity profiling and numerous other peptide microarrays for vaccine development as well as cancer, infectious disease, and autoimmune research. What we can do with our peptide microarrays is narrow down the binding site of an antibody to its antigen, not only down to the epitope with single amino acid resolution, but also to identify conserved and variable amino acid positions and from there, deduce the cross-reactivity of an antibody.

PEPperPRINT has ~30 readily available Viral peptide chips (eg: H5N1, Zika (Mr766),CHIKV, HBV, DENV etc.) which includes also PEPperCHIP® SARS-CoV-2 Proteome & the PEPperCHIP® Pan-Corona Spike Protein Microarrays. We are currently performing many large-scale studies of Covid-19 Immune response study across various Institute of National Importance.

Association Partner

Association of Biotechnology Led Enterprises

Association of Biotechnology Led Enterprises - ABLE is a not-for-profit pan-India forum that represents the Indian Biotechnology Sector. It was launched in April 2003, after industry leaders felt a need to form an exclusive forum to represent the Indian Biotechnology Sector.

ABLE has over 400 members from all across India representing all verticals of the sector like Agribiotech, Bio-pharma, Industrial biotech, Bioinformatics, Investment banks and Venture Capital firms, leading Research and Academic Institutes and Law Firms and Equipment Suppliers.

The primary focus of ABLE is to accelerate the pace of growth of the Biotechnology sector in India, through partnering with the Government in their biotechnology initiatives to deliver optimal policies and create a positive regulatory environment, encouraging entrepreneurship and investment in the sector, providing a platform for domestic and overseas companies to explore collaboration and partnerships, forging stronger links between academia and industry and showcasing the strengths of the Indian biotech sector. For more details please visit www.ableindia.in

Media Partners

Delegate Registration fees : 15,000 + 18% GST

Agenda

Key Topics for 25th August

  • Indian Vaccine Industry: Present And Futuritics Approaches
  • Vaccine Production & its Manufacturing
  • Efficient Technology Transfers: Basic need for Vaccine R&D and Manufacturing.
  • mRNA vaccine revolution
  • Advances in Vaccine Analytical Methods

KEY Topics for Day 26th August

  • Covid Vaccines – Present Status & Future Strategies while Preparing For Future Pandemics
  • Addressing vaccine preparedness for emerging and re-emerging diseases and future outbreaks?
  • Broadly protective and multi-valent vaccines and monoclonal antibodies for various bacterial and viral infections
  • Logistics, last mile, and innovations to ensure successful deployment of next generation vaccines
  • Connecting Human and Veterinary Vaccine Development: Looking from a One Health perspective

Contact Us

For speaking opportunities

pradeep@bluetech-media.com
+91 9821739900

For Delegates Registration

bdm@bluetech-media.com
+91 7718843607

Register Now